Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents
The Purpose of this study is to evaluate the safety of ME-609 for the treatment of recurrent herpes labialis in adolescents.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open Label, Multi-Centre, Phase III, Subject Initiated Safety Study of ME-609 in Treatment of Recurrent Herpes Simplex Labialis in Adolescents|
- Adverse Event [ Time Frame: 3 weeks after last dose ] [ Designated as safety issue: Yes ]
|Study Start Date:||October 2006|
|Study Completion Date:||September 2007|
|Primary Completion Date:||September 2007 (Final data collection date for primary outcome measure)|
Topical treatment 5 times daily for 5 days
The objective of the study was to evaluate the safety of ME-609 for the treatment of herpes labialis recurrences in immunocompetent adolescents, 12 - 17 years of age, following a 5-day treatment with 5-time daily topical administration.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00375570
|Principal Investigator:||Anders Strand, MD PhD||Department of Medical Sciences, Dermatology and Venereology University Hospital, Uppsala, Sweden|